v3.20.1

Share-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Share-based Compensation |
(1 8) | SHARE-BASED COMPENSATION
2005 Share incentive plan In April 2005, the Company adopted a share incentive plan (the “2005 Plan”), pursuant to which the Company is authorized to issue options to officers, employees, directors and consultants of the Group to purchase up to 2,894,000 of its common shares. In October 2007, the Company’s board of directors approved an increase in the number of shares reserved for issuance under the 2005 Plan to 3,310,300 shares. The 2005 Plan expired in April 2015. Options awards provide for accelerated vesting if there is a change in control (as defined in the 2005 Plan). 2008 Share incentive plan On January 7, 2008, the Company adopted a share incentive plan (the “2008 Plan”), pursuant to which the Company is authorized to issue options and other share-based awards to officers, employees, directors and consultants of the Group to purchase up to 336,307 of its common shares, plus, unless the board of directors determines a lesser amount, an annual increase on January 1 of each calendar year beginning in 2009 equal to the lesser of 1) one percent of the number of shares issued and outstanding on December 31 of the immediately preceding calendar year, and 2) 336,307 shares (the “replenish terms”). The 2008 Plan expires in ten years. Options awards provide for accelerated vesting if there is a change in control (as defined in the 2008 Plan). On December 30, 2016, the Company amended the 2008 Plan to increase the number of Common Shares of the Company reserved for issuance to 5,726,763 shares and extend the plan together with the replenish terms for ten years from December 30, 2016 (the “Amendment and Restatement of 2008 Plan”). On October 26, 2018, the Company amended and restated the Amendment and Restatement of 2008 Plan to increase the number of Common Shares the Company reserved for issuance to 6,965,846 shares, extend its terms to last till October 25, 2028 and change the number of common shares automatically added to the option pool on each calendar year during its term to an amount equal to the lesser of (i) one percent of the total number of common shares issued and outstanding on December 31 of the immediately preceding calendar year, or (ii) such number of common shares as may be established by the board of directors (the “Second Amendment and Restatement of 2008 Plan”). As of December 31, 2019, 7,423,815 shares were reserved for issuance under the Second Amendment and Restatement of 2008 Plan. Under both the 2005 Plan and 2008 Plan (including the original and both versions of the Amendment and Restatement), share options are generally granted with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting ratably over the following 36 months, unless a shorter or longer duration is established at the time of the option grant. Share options are granted at an exercise price equal to or as an average over a certain number of trading days of the fair market value of the Company’s share at the date of grant and expire 10 years from the grant date. Under the 2008 Plan (including the original and both versions of the Amendment and Restatement), non-vested shares are generally granted with a graded vesting as to 25% at the end of each year from the grant date over 4 years, or with certain percentage vesting on the grant date or first anniversary of the grant date and the remaining portion vesting ratably over the following 36 months, unless a shorter or longer duration is established at the time of the grant. For the graded vesting share options and non-vested shares, the Company recognizes the compensation cost over the requisite service period for each separately vesting portion of the award as if the award is, in substance, multiple awards. In January 2017, 2,700,000 non-vested shares were granted to employees and officers with a graded vesting as to 25% at the end of each year from the grant date over 4 years and 900,000 share options were granted to Company’s employees and officers, 25% of the options vest on the first anniversary of the grant date with the remaining 75% vesting evenly over the following 36 months. The exercise price of these options is USD 1.705 per common share. In August 2017, 50,000 share options were granted to an employee, 25% of the options vest on the first anniversary of the grant date with the remaining 75% vesting evenly over the following 36 months. The exercise price of these options is USD 2.35 per common share. In July 2018, 129,168 share options and 1,262,250 non-vested shares were cancelled in connection with the ATA Online Sale Transaction. RMB 6,753,771 compensation costs were accelerated and recognized for the year ended December 31, 2018. In November 2018, 1,772,584 share options, including 1,215,114 vested share options and 557,470 non-vested share options were cancelled in accordance with the board of directors resolutions. RMB 877,321 of compensation costs were accelerated and recognized for the year ended December 31, 2018. In November 2018, 1,452,600 share options were issued to certain employees and officers with 4 years’ service condition and annual performance targets for the year 2018, 2019, 2020 and 2021, among which 363,150 share options were granted in November 2018 and the remaining portion will be granted when the employee knows the specific performance target. As the performance condition for the year 2018 was not achieved, no compensation cost was recognized for these share options. In addition, 690,000 share options were granted to employees and officers, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting ratably over the following 36 months. The exercise price of these options is USD 0.578 per common share. In addition, 800,000 non-vested shares were granted to directors, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting ratably over the following 36 months. In December 2018, 1,772,584 shares were granted to employees and officers, among which 1,412,336 shares vested immediately on the grant date and the remaining shares vested for a period from January 1, 2019 to September 1, 2021. In January and March 2019, 50,000 share options and 20,000 share options were granted to employees and officers, among which with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting ratably over the following 36 months. The exercise prices of these two tranches options are USD 0.4868 and USD 0.532 per common share respectively. A summary of the share options activities for nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019 is presented below:
|  |  |  |  |  | Weighted |  |  | Weighted |  | Aggregate
|  |  |  |  |  | average |  |  | remaining |  | intrinsic
|  | Number of |  |  | exercise |  |  | contractual |  | value
|  | shares |  |  | USD |  |  | years |  | USD
Outstanding as of March 31, 2017 |  |  | 2,451,067 |  |  |  | 2.21 |  |  |  |  |
Granted |  |  | 50,000 |  |  |  | 2.35 |  |  |  |  |
Exercised |  |  | — |  |  |  | — |  |  |  |  |
Forfeited |  |  | (50,000 | ) |  |  | 1.71 |  |  |  |  |
Expired |  |  | (74,000 | ) |  |  | 3.60 |  |  |  |  |
Outstanding as of December 31, 2017 |  |  | 2,377,067 |  |  |  | 2.18 |  |  |  |  |
Granted |  |  | 1,053,150 |  |  |  | 0.58 |  |  |  |  |
Exercised |  |  | (119,792 | ) |  |  | 1.77 |  |  |  |  |
Forfeited |  |  | (123,438 | ) |  |  | 1.71 |  |  |  |  |
Cancelled |  |  | (1,901,752 | ) |  |  | 2.13 |  |  |  |  |
Expired |  |  | (143,023 | ) |  |  | 3.89 |  |  |  |  |
Outstanding as of December 31, 2018 |  |  | 1,142,212 |  |  |  | 0.67 |  |  |  |  |
Granted |  |  | 70,000 |  |  |  | 0.50 |  |  |  |  |
Exercised |  |  | — |  |  |  | — |  |  |  |  |
Forfeited |  |  | (809,712) |  |  |  | 0.61 |  |  |  |  |
Cancelled |  |  | — |  |  |  | — |  |  |  |  |
Expired |  |  | — |  |  |  | — |  |  |  |  |
Outstanding as of December 31, 2019 |  |  | 402,500 |  |  |  | 0.75 |  |  |  |  |
Vested and expected to vest as of December 31, 2019 |  |  | 402,500 |  |  |  | 0.75 |  |  | 8.59 |  | 35,753
Exercisable as of December 31, 2019 |  |  | 122,082 |  |  |  | 0.90 |  |  | 8.33 |  | 8,879
The aggregate intrinsic value of options outstanding and exercisable at December 31, 2019, was determined based on the closing price of the Company’s common shares on December 31, 2019. Information relating to options outstanding and exercisable as of December 31, 2019 is as follows:
Options outstanding as of December 31, 2019 |  | Options exercisable as of December 31, 2019
|  | Exercise |  | Remaining |  |  |  | Exercise |  | Remaining
Number of |  | Price |  | Contractual |  | Number |  | Price |  | Contractual
Shares |  | per Share |  | Life |  | of Shares |  | per Share |  | Life
|  | USD |  | Years |  |  |  | USD |  | Years
62,500 |  | 1.71 |  | 7.05 |  | 35,416 |  | 1.71 |  | 7.05
320,000 |  | 0.58 |  | 8.85 |  | 86,666 |  | 0.58 |  | 8.85
20,000 |  | 0.53 |  | 9.21 |  | — |  | — |  | —
402,500 |  | 0.75 |  | 8.59 |  | 122,082 |  | 0.90 |  | 8.33
The Company calculated the fair value of the share options on the grant date, for nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019, using the Black-Scholes-Merton pricing valuation model. The assumptions used in the valuation model are summarized as follows:
|  | Nine months ended December 31 |  |  | Twelve months ended December 31 |  |  | Twelve months ended December 31
|  | 2017 |  |  | 2018 |  |  | 2019
Expected dividend yield |  |  | 8.7% |  |  |  | 0% |  |  | 0%
Expected volatility |  |  | 60% |  |  |  | 57% |  |  | 55%/54%
Expected term |  |  | 6.08 |  |  | 5.11/6.11 |  |  | 6.08
Risk-free interest rate (per annum) |  |  | 1.96% |  |  | 3.05%/3.10% |  |  | 2.53%/2.45%
The expected volatility was based on the historical volatilities of the Company. The expected term was related to the period of time the options are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the United States treasury yield curve in effect at the time of grant. Compensation expense recognized for non-vested share options for nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019 is allocated to the following expense items:
|  | Nine months ended December 31 |  |  | Twelve months ended December 31 |  |  | Twelve months ended December 31
|  | 2017 |  |  | 2018 |  |  | 2019
|  | RMB |  |  | RMB |  |  | RMB
Research and development |  |  | 476,994 |  |  |  | 157,355 |  |  | 68,016
Sales and marketing |  |  | 272,568 |  |  |  | 70,915 |  |  | —
General and administrative |  |  | 2,353,681 |  |  |  | 2,024,940 |  |  | 345,991
Total share-based compensation expense |  |  | 3,103,243 |  |  |  | 2,253,210 |  |  | 414,007
As of December 31, 2019, RMB 331,885 of total unrecognized compensation expense related to non-vested share options is expected to be recognized over a weighted average period of approximately 2.78 years. Non-vested shares A summary of the non-vested shares activities for nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019 is presented below:
|  |  |  |  |  | Weighted average |
|  | Number |  |  | grant date |
|  | of shares |  |  | fair value |
|  | USD |  |  |  |  |
Outstanding at March 31, 2017 |  |  | 2,700,000 |  |  |  | 1.661 |
Granted |  |  | — |  |  |  | — |
Vested |  |  | (60,000) |  |  |  | 2.145 |
Forfeited |  |  | (15,000) |  |  |  | 1.650 |
Outstanding at December 31, 2017 |  |  | 2,625,000 |  |  |  | 1.650 |
Granted |  |  | 2,572,584 |  |  |  | 0.537 |
Vested |  |  | (2,068,586) |  |  |  | 0.872 |
Forfeited |  |  | (71,250) |  |  |  | 1.650 |
Cancelled |  |  | (1,262,250) |  |  |  | 1.650 |
Outstanding at December 31, 2018 |  |  | 1,795,498 |  |  |  | 0.951 |
Granted |  |  | — |  |  |  | — |
Vested |  |  | (693,362) |  |  |  | 0.885 |
Forfeited |  |  | — |  |  |  | — |
Cancelled |  |  | — |  |  |  | — |
Outstanding at December 31, 2019 |  |  | 1,102,136 |  |  |  | 0.993 |
The total fair value of shares vested during nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019 was USD 148,500, USD 2,591,875 and USD 461,309 respectively. Upon vesting of the non-vested shares, the Company withholds shares issued to the employees to meet the relevant minimum tax withholding requirements. For nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019, the Company withheld 11,252, 93,496 and 28,456 vested shares upon vesting of the non-vested shares to satisfy the minimum tax withholding obligation. Compensation expense recognized for non-vested shares for nine months ended December 31, 2017, the year ended December 31, 2018 and the year ended December 31, 2019 is allocated to the following expense items:
|  | Nine months ended December 31 |  |  | Twelve months ended December 31 |  |  | Twelve months ended December 31
|  | 2017 |  |  | 2018 |  |  | 2019
|  | RMB |  |  | RMB |  |  | RMB
Cost of revenues |  |  | — |  |  |  | — |  |  | —
Research and development |  |  | 516,339 |  |  |  | 240,441 |  |  | 367,313
Sales and marketing |  |  | 258,170 |  |  |  | 96,058 |  |  | —
General and administrative |  |  | 2,908,303 |  |  |  | 7,119,658 |  |  | 4,028,134
Total share-based compensation expense |  |  | 3,682,812 |  |  |  | 7,456,157 |  |  | 4,395,447
As of December 31, 2019, RMB 2,077,009 of total unrecognized compensation expense related to non-vested shares is expected to be recognized over a weighted average period of approximately 2.17 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration